购物车
- 全部删除
- 您的购物车当前为空
JD-5037 是一种 CB1R 有效拮抗剂,IC50=1.5 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
JD-5037 是一种 CB1R 有效拮抗剂,IC50=1.5 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 297 | 现货 | |
2 mg | ¥ 437 | 现货 | |
5 mg | ¥ 713 | 现货 | |
10 mg | ¥ 1,160 | 现货 | |
25 mg | ¥ 2,150 | 现货 | |
50 mg | ¥ 3,660 | 现货 | |
100 mg | ¥ 5,330 | 现货 | |
500 mg | ¥ 10,900 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 898 | 现货 |
产品描述 | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
靶点活性 | CB1 receptor:1.5 nM |
体内活性 | JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia as well as reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. |
动物实验 | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters |
别名 | JD 5037 |
分子量 | 572.51 |
分子式 | C27H27Cl2N5O3S |
CAS No. | 1392116-14-1 |
Smiles | CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |
密度 | 1.40 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (87.33 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容